Sinocare Inc.
Sinocare
Sinocare is Asia's largest dedicated blood glucose monitoring manufacturer and a leading global player in diabetes care, founded in 2002 in Changsha, Hunan, China. With annual revenue of ¥4.659 billion, the company serves patients in 135+ countries with affordable glucose monitoring solutions. Sinocare is transitioning from traditional BGM to next-generation CGM technology.
Strengths: Massive volume-driven cost advantages with 48.74% gross margin; dominant position in price-sensitive emerging markets (135+ countries covered); ¥275M R&D investment in CGM technology development; fully automated production facilities in Changsha headquarters for extreme scale efficiency.
Weaknesses: Net profit collapsed 71.61% to ¥92.65M due to VBP price cuts and CGM investment; heavy R&D spend (5.89% of revenue) pressured near-term earnings; faces existential competitive pressure from Abbott and Dexcom in CGM segment.Read MoreShow Less
Strengths: Massive volume-driven cost advantages with 48.74% gross margin; dominant position in price-sensitive emerging markets (135+ countries covered); ¥275M R&D investment in CGM technology development; fully automated production facilities in Changsha headquarters for extreme scale efficiency.
Weaknesses: Net profit collapsed 71.61% to ¥92.65M due to VBP price cuts and CGM investment; heavy R&D spend (5.89% of revenue) pressured near-term earnings; faces existential competitive pressure from Abbott and Dexcom in CGM segment.
Listed market data
300298 · SZSE · weeklyHistory →- Market cap
- $1.3 B
- Share price
- ≈ CNY 2.39
- 1Y change
- -5.0%
- Recent change
- +9.6%
- IPO price
- +200.4%
- Revenue (TTM)
- ¥4.7 B
10-22 → 10-23
CNY 29.00 · from 2012-03-19
Financial history
Full market history- 2026-10CNY 18.01$1.3 B+10.5%
- 2026-09CNY 16.30$1.2 B+2.1%
- 2026-08CNY 15.96$1.2 B-2.4%
- 2026-07CNY 16.35$1.2 B+17.2%
- 2026-06CNY 13.95$1 B-10.4%
- 2026-05CNY 15.57$1.2 B-6.4%
- 2026-04CNY 16.63$1.2 B+4.8%
- 2026-03CNY 15.87$1.2 B-10.9%
- 2026-02CNY 17.82$1.3 B+1.5%
- 2026-01CNY 17.55$1.3 B+2.6%
- 2025-12CNY 17.11$1.3 B-3.8%
- 2025-11CNY 17.78$1.3 B—
In the press
All coverage →5 latest headlines1- Connected Chronic Care Systems: Sinocare Links Home, Pharmacy and Hospital Monitoring - Trend Hunterwww.trendhunter.com2026-10-01
- Sinocare Showcases Integrated Chronic Disease Management Solutions at EASD 2026 - PR Newswirewww.prnewswire.com2026-09-30
- Toward standardized continuous glucose monitoring validation: lessons from the Sinocare iCan i3 accuracy study - Frontierswww.frontiersin.org2026-09-01
- Practical PI lessons at the UPC Court of Appeal: 8 things Abbott v Sinocare teaches us (via Passle) - Bristowsinquisitiveminds.bristows.com2026-05-28
- Another win for Abbott as Court of Appeal grants PI against Sinocare - JUVE Patentwww.juve-patent.com2026-04-20
• Traditional BGM blood glucose monitoring test strips and meters
• Developing CGM continuous glucose monitoring systems
• Diabetes management software and mobile applications
• Point-of-care HbA1c testing devices
• Hospital glucose monitoring systems
• Diabetes education and patient support services
Quick Facts
Headquarters
Changsha, Hunan, China
Founded
2002
Employees
8000+
Revenue
¥4.7 B
Market cap
$1.3 B
Factories
4+ factories in China
Presence
135+ Countries
Listing
SZSE: 300298
Categories
Related
Similar listed companies
- Apple Inc.· $5 T
- Amazon.com, Inc.· $2.7 T
- Eli Lilly and Company· $1.1 T
- Samsung Electronics Co., Ltd.· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website SZSE: 300298 , Data Sources & Methodology
Sinocare Official Website
Sinocare 2025 Annual Revenue
Sinocare 2025 Board Report
Sinocare - Wikipedia